Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients requiring supplemental or total nutritional support,Off-label: Not typically used off-label due to specific formulation
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are metabolized via transamination and deamination in the liver; dextrose undergoes glycolysis and enters the citric acid cycle. Electrolytes are excreted or reabsorbed renally.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: negligible (<5% bound). Dextrose: negligible. Electrolytes: variable; calcium ~40% bound to albumin, magnesium ~30% bound to albumin, potassium and sodium minimally bound (<5%).
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids: total body water (~0.5-0.7 L/kg). Dextrose: total body water (~0.2 L/kg initially). Electrolytes: sodium ~0.6 L/kg, potassium ~0.4 L/kg, calcium ~0.2 L/kg, magnesium ~0.3 L/kg.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Not applicable; administered as intravenous infusion only (bioavailability 100% by IV route). No oral bioavailability.
Intravenous: 100%.
In GFR 30-59 m L/min: reduce amino acid dose by 50% and monitor electrolytes closely. If GFR <30 m L/min: avoid or use only with extreme caution, typically restrict protein to 0.6-0.8 g/kg/day and adjust electrolytes per serum levels.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh Class A: no adjustment necessary. Child-Pugh B: reduce amino acid dose to 0.8-1.2 g/kg/day. Child-Pugh C: avoid due to risk of encephalopathy; if essential, restrict to 0.5-0.7 g/kg/day with branched-chain amino acid enrichment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Neonates and infants: 2-3 g/kg/day amino acids and 10-15 g/kg/day dextrose, titrating gradually. Children: 1-2 g/kg/day amino acids and 5-10 g/kg/day dextrose; rate not to exceed 0.2-0.4 g/kg/h dextrose. Adjust electrolytes per daily requirements.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Elderly patients: start at lower end of dose range; monitor renal function and serum electrolytes closely. Typical amino acid dose 1.0-1.2 g/kg/day, dextrose dose adjusted to avoid hyperglycemia; infusion rate not to exceed 2 mg/kg/min.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not for use in patients with severe electrolyte imbalances, severe liver disease, or severe renal impairment. May cause hyperglycemia, electrolyte abnormalities, or volume overload. Must be used under medical supervision.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Monitor serum glucose, electrolytes, fluid status, and renal function,Risk of hyperglycemia in diabetic patients,Risk of electrolyte disturbances including hyperkalemia, hypercalcemia, and hyperphosphatemia,Avoid in patients with galactosemia or fructose intolerance,Use caution in hepatic or renal impairment
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Severe electrolyte imbalance,Severe liver disease (e.g., hepatic coma),Severe renal impairment (anuria, oliguria),Galactosemia,Fructose intolerance
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No direct food interactions as this is an intravenous product. However, oral intake may be restricted or monitored due to underlying medical conditions (e.g., diabetes, renal failure). Ensure consistent carbohydrate intake if transitioning to oral feeding.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, amino acids and dextrose are endogenous substances; electrolyte imbalances can cause fetal harm. In first trimester: avoid unless maternal benefit outweighs risk; deficiencies in essential nutrients may be teratogenic. Second/third trimester: use only if clearly needed; monitor for hyperglycemia (risk of fetal macrosomia, neonatal hypoglycemia).
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Excretion into breast milk: unknown. Components are endogenous, so transfer is likely minimal. No specific M/P ratio available. Considered probably compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal levels are abnormal.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy requires increased nutritional demands; no specific dose adjustments are established. Monitor blood glucose due to insulin resistance; consider reducing dextrose infusion if hyperglycemia develops. Adjust electrolytes based on serial monitoring. Start at lower infusion rates and titrate slowly.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
CLINIMIX E 2.75/25 is a dual-chamber bag containing amino acids and dextrose with electrolytes, including calcium. Do not use if seals are broken or if solution is discolored. Must be administered via central line due to high dextrose concentration (25%). Avoid simultaneous administration with ceftriaxone due to calcium-ceftriaxone precipitation risk. Monitor serum electrolytes, blood glucose, and liver function tests closely. Not for use in patients with severe hepatic or renal impairment.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication provides nutrition through a vein and must be given by a healthcare professional.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, itching, difficulty breathing).,Inform your healthcare provider if you have a history of diabetes, kidney disease, or liver problems.,This solution contains added calcium; avoid taking additional calcium supplements without doctor approval.,You may experience changes in blood sugar; symptoms of high or low blood sugar (e.g., excessive thirst, urination, shakiness) should be reported.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.